Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21404137 | 1.00 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL7032667 | 0.80 | TSHR (0.35) | ALDH1A1TSHR | |
| SCHEMBL6444472 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL2162960 | 0.75 | — | — | |
| SCHEMBL1783577 | 0.74 | — | — | |
| SCHEMBL1284382 | 0.72 | — | — | |
| SCHEMBL21404223 | 0.71 | — | — | |
| SCHEMBL21404225 | 0.71 | — | — | |
| SCHEMBL21404226 | 0.71 | — | — | |
| SCHEMBL466695 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2023-12-05 | — | — | US | disclosed |
| CN-111741948-B | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3760619-B1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2023-10-25 | — | — | EP | disclosed |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
| EP-3760619-A1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-06 | — | — | EP | disclosed |
| CN-111741948-A | Saturated ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2020-10-02 | — | — | CN | disclosed |
| US-20190300490-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300490-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | RORC, RORB, RORA | ALDH1A1 237/4885TSHR 1091/4885 |
| US-11834421-B2 | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | RORC, RORB, RORA | ALDH1A1 252/4885TSHR 1026/4885 |
| US-20220119355-A1 | SATURATED-RING-FUSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | RORC, RORB, RORA | ALDH1A1 252/4885TSHR 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.